BIVF funding more than doubled to 250 M€
Boehringer Ingelheim increases funding for its corporate venture fund, the Boehringer Ingelheim Venture Fund (BIVF), from EUR 100 to 250 million
Search
Interview Dr Mehdi Shahidi
Interview with Dr Mehdi Shahidi, Chief Medical Officer and Head of the Corporate Division Medicine at Boehringer Ingelheim
Vicadrostat (BI 690517) + empagliflozin: Aldosterone synthase inhibitor + SGLT2 inhibitor | HFpEF
Vicadrostat (BI 690517) + empagliflozin: Aldosterone synthase inhibitor + SGLT2 inhibitor | HFpEF
Vicadrostat (BI 690517) + empagliflozin
Vicadrostat (BI 690517) + empagliflozin
Brigitte Fuhr
Brigitte Fuhr, our Head of Central Data Science, joined our team to make millions of lives better. Now she’s working on a global program that will transform our ability to develop ground-breaking treatments.
Strategic-collaboration-with-EnaraBio
Boehringer Ingelheim and Enara Bio enter strategic collaboration and licensing agreement to discover novel shared antigens for cancer immunotherapies.
FIBRONEER™ Ph3 trials in patients with IPF & other PF-ILDs
Donald Zoz, M.D., Director and Senior Clinical Program Leader for Pulmonary Fibrosis, discusses the FIBRONEER™ global clinical program
Survodutide (BI 456906): GLP1/GCGR agonist | obesity
Survodutide (BI 456906): GLP1/GCGR agonist | obesity
Stroke
Stroke
About Office Hours
Boehringer Ingelheim Office Hours mentors early-stage life-science companies providing access to expertise, an industry perspective and feedback.
"Medical innovations and healthcare for everyone"
African Americans are often excluded from healthcare options and medical innovations. We want to learn how we can better serve them.
Boehringer Ingelheim strong growth pipeline acceleration 2023
Boehringer Ingelheim reports strong growth in 2023 and accelerates late-stage pipeline
SIRPα antagonist
SIRPα antagonist
Our Venture Fund on the search for groundbreaking trends
The Boehringer Ingelheim Venture Fund acquires minority stakes in biotech start-ups, and even supports the majority before and during their founding.
BTD for GlyT1 in Schizophrenia
Boehringer Ingelheim’s Investigational Treatment for Cognitive Impairment Associated with Schizophrenia receives FDA Breakthrough Therapy Designation
FRONTLINE becomes Brand of the Year 2019-2020
FRONTLINE becomes ‘Brand of the Year’ 2019-2020 in World Branding Awards
Brazil boosts biosecurity in dairy farms
We partnered with Embrapa to help farmers and local authorities set best practices in biosecurity for dairy through a biosecurity certificate.
Rabies prevention local action partnering organizations
Global rabies prevention needs local action. Together with partnering organizations, we’re using pilot projects to find the right approach.
Boehringer Ingelheim and GST prepared bring innovation to equine market
Boehringer Ingelheim and Global Stem Cell Technology are prepared to bring groundbreaking innovation to equine market
Living with pulmonary fibrosis and finding hope
From caregiver to co-founder of the European Pulmonary Fibrosis Federation, Liam Galvin shares about his experience, and the impact of ongoing research
Partnering in Central Nervous System Diseases
We are looking for new early-science collaborations. Join our expanding community of innovation partners in central nervous system diseases.
Agreement-to-acquire-Labor-Dr.-Merk
Boehringer Ingelheim to acquire Labor Dr. Merk & Kollegen to strengthen its next generation cancer immunology program
Groundbeaking of vaccine production center in France
Boehringer Ingelheim breaks ground on its strategic vaccine production center for veterinary public health
BI_X_Shanghai
Boehringer Ingelheim opens a second branch of its digital lab in Shanghai
1885-1948: Innovative beginnings
The Boehringer Ingelheim history from its start in 1885 to 1948, with milestones and important products